Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 15/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788269 | 0.98 | ADRB2 (0.50) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL12788271 | 0.92 | STAT3 (0.44) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL3659573 | 0.91 | ADRB2 (0.51) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL6521689 | 0.90 | ADRB2 (0.49) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL3659855 | 0.89 | STAT3 (0.45) | ADRB2STAT3PRKAA2 | |
| SCHEMBL6520829 | 0.89 | STAT3 (0.42) | ADRB2STAT3PRKAA2MLNR | |
| SCHEMBL3659359 | 0.88 | STAT3 (0.43) | ADRB2STAT3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL6520781 | 0.87 | ADRB2 (0.41) | ADRB2STAT3PRKAA2 | |
| SCHEMBL6519504 | 0.87 | PARP1 (0.45) | ADRB2STAT3PRKAA2 | |
| SCHEMBL3711560 | 0.86 | PARP1 (0.41) | ADRB2STAT3PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2215077-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | GPR119, GIPR, GPR39 | ADRB2 126/4885STAT3 1637/4885PRKAA2 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.